Clinical Trial Update: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating lenvatinib in combination with everolimus for pediatric patients with recurrent and refractory solid tumors, including CNS tumors, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And Refractory Solid Tumors
• Central Nervous System Tumors
• Solid Tumors

Drugs mentioned

• Everolimus (everolimus)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Recurrent and Refractory Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-30